BioLineRx (BLRX) Operating Expenses (2011 - 2025)
BioLineRx (BLRX) posted quarterly Operating Expenses of -$3.5 million for Q4 2025, up 6.37% year-over-year from -$3.3 million in Q4 2024, and down 38.82% quarter-over-quarter from -$2.6 million in Q3 2025.
BioLineRx (BLRX) Operating Expenses (2011 - 2025) Analysis & Trends
BioLineRx's Operating Expenses history runs 14 years deep, the most recent figure standing at -$3.5 million for Q4 2025.
- In Q4 2025, Operating Expenses rose 6.37% year-over-year to -$3.5 million; the TTM figure through Dec 2025 stood at -$11.2 million (up 27.36% YoY), while the FY2025 annual figure was -$11.2 million, up 27.36% from the prior year.
- Operating Expenses for Q4 2025 stood at -$3.5 million, down from -$2.6 million in the prior quarter.
- The five-year high for Operating Expenses was $4.3 million in Q2 2022, with the low at -$6.3 million in Q4 2021.
- The 5-year median for Operating Expenses is -$4.1 million (2023), against an average of -$3.5 million.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses slumped 199.19% in 2023, then soared 35.52% in 2025.
- BioLineRx's Operating Expenses stood at -$6.3 million in 2021, then advanced by 20.2% to -$5.0 million in 2022, then decreased by 5.19% to -$5.3 million in 2023, then grew by 28.79% to -$3.8 million in 2024, then advanced by 6.37% to -$3.5 million in 2025.
- Business Quant data shows BLRX's Operating Expenses at -$3.5 million in Q4 2025, -$2.6 million in Q3 2025, and -$2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | BioLineRx | 7.21 Bn | 7.21 Bn | 154,000.00 | -3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.54 Mn |
| Sep 30, 2025 | -2.55 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Mar 31, 2025 | -2.61 Mn |
| Dec 31, 2024 | -3.78 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -3.85 Mn |
| Mar 31, 2024 | -3.88 Mn |
| Dec 31, 2023 | -5.31 Mn |
| Sep 30, 2023 | -4.23 Mn |
| Jun 30, 2023 | -4.31 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -5.05 Mn |
| Sep 30, 2022 | -5.76 Mn |
| Jun 30, 2022 | 4.35 Mn |
| Mar 31, 2022 | -5.44 Mn |
| Dec 31, 2021 | -6.33 Mn |
| Sep 30, 2021 | -5.97 Mn |
| Jun 30, 2021 | 4.10 Mn |
| Mar 31, 2021 | -5.30 Mn |